Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia
D Haffner, F Emma, DM Eastwood… - Nature Reviews …, 2019 - nature.com
X-linked hypophosphataemia (XLH) is the most common cause of inherited phosphate
wasting and is associated with severe complications such as rickets, lower limb deformities …
wasting and is associated with severe complications such as rickets, lower limb deformities …
Rationale and plan for vitamin D food fortification: a review and guidance paper
S Pilz, W März, KD Cashman, ME Kiely… - Frontiers in …, 2018 - frontiersin.org
Vitamin D deficiency can lead to musculoskeletal diseases such as rickets and
osteomalacia, but vitamin D supplementation may also prevent extraskeletal diseases such …
osteomalacia, but vitamin D supplementation may also prevent extraskeletal diseases such …
[HTML][HTML] Burosumab therapy in children with X-linked hypophosphatemia
TO Carpenter, MP Whyte, EA Imel… - … England Journal of …, 2018 - Mass Medical Soc
Background X-linked hypophosphatemia is characterized by increased secretion of
fibroblast growth factor 23 (FGF-23), which leads to hypophosphatemia and consequently …
fibroblast growth factor 23 (FGF-23), which leads to hypophosphatemia and consequently …
Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial
Background X-linked hypophosphataemia in children is characterised by elevated serum
concentrations of fibroblast growth factor 23 (FGF23), hypophosphataemia, rickets, lower …
concentrations of fibroblast growth factor 23 (FGF23), hypophosphataemia, rickets, lower …
Calcium deficiency worldwide: Prevalence of inadequate intakes and associated health outcomes
Dietary calcium deficiency is considered to be widespread globally, with published
estimates suggesting that approximately half of the world's population has inadequate …
estimates suggesting that approximately half of the world's population has inadequate …
Vitamin D testing and treatment: a narrative review of current evidence
S Pilz, A Zittermann, C Trummer… - Endocrine …, 2019 - ec.bioscientifica.com
Vitamin D testing and treatment is a subject of controversial scientific discussions, and it is
challenging to navigate through the expanding vitamin D literature with heterogeneous and …
challenging to navigate through the expanding vitamin D literature with heterogeneous and …
The lifelong impact of X-linked hypophosphatemia: results from a burden of disease survey
A Skrinar, M Dvorak-Ewell, A Evins… - Journal of the …, 2019 - academic.oup.com
Context X-linked hypophosphatemia (XLH) is characterized by excess fibroblast growth
factor 23 (FGF23), hypophosphatemia, skeletal abnormalities, and growth impairment. We …
factor 23 (FGF23), hypophosphatemia, skeletal abnormalities, and growth impairment. We …
Effect of burosumab compared with conventional therapy on younger vs older children with X-linked hypophosphatemia
LM Ward, FH Glorieux, MP Whyte… - The Journal of …, 2022 - academic.oup.com
Context Younger age at treatment onset with conventional therapy (phosphate salts and
active vitamin D; Pi/D) is associated with improved growth and skeletal outcomes in children …
active vitamin D; Pi/D) is associated with improved growth and skeletal outcomes in children …
Vitamin D insufficiency: Definition, diagnosis and management
R Bouillon, G Carmeliet - Best practice & research Clinical endocrinology & …, 2018 - Elsevier
Severe vitamin D deficiency can be defined as the dose of vitamin D or serum 25OHD
concentrations needed to prevent nutritional rickets or osteomalacia. There is large …
concentrations needed to prevent nutritional rickets or osteomalacia. There is large …
Efficacy and safety of burosumab in children aged 1–4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial
MP Whyte, TO Carpenter, GS Gottesman… - The lancet Diabetes & …, 2019 - thelancet.com
Background Children with X-linked hypophosphataemia have high concentrations of
circulating phosphatonin fibroblast growth factor 23 (FGF23), which causes renal phosphate …
circulating phosphatonin fibroblast growth factor 23 (FGF23), which causes renal phosphate …